Difference between revisions of "Documentation/Nightly/Extensions/PercutaneousApproachAnalysis"
Line 24:  Line 24:  
[[File:synthetic.png360x240px]][[File:accessibility clinical.png540x210px]]<br>  [[File:synthetic.png360x240px]][[File:accessibility clinical.png540x210px]]<br>  
The Percutaneous Approach Analysis is used to calculate and visualize the accessibility of liver tumor with a percutaneous approach. The software uses the “raytracing” method in which the target tumor serves as a light source to identify the area of the skin that allows direct approach to the target tumor with a straight needle. This software takes the Body Surface model, Obstacle model, and a fiducial point in the liver model as inputs. The software also examines each line that connects the fiducial point and the center of each polygon cell on the Body Surface model and check if the line intersects the Obstacle model. If it does not intersect, the cell is identified as an accessible area. The polygon is colored based on the accessibility to visualize the results in 3D. For quantitative analysis, the software calculates the ratio of the total accessible area to the total area of the Body Surface model as the accessibility score (AS) for the specified fiducial point in the liver. Additionally, the software calculates and visualizes the distance between the target tumor and each polygon of the accessible area on the Body Surface model.  The Percutaneous Approach Analysis is used to calculate and visualize the accessibility of liver tumor with a percutaneous approach. The software uses the “raytracing” method in which the target tumor serves as a light source to identify the area of the skin that allows direct approach to the target tumor with a straight needle. This software takes the Body Surface model, Obstacle model, and a fiducial point in the liver model as inputs. The software also examines each line that connects the fiducial point and the center of each polygon cell on the Body Surface model and check if the line intersects the Obstacle model. If it does not intersect, the cell is identified as an accessible area. The polygon is colored based on the accessibility to visualize the results in 3D. For quantitative analysis, the software calculates the ratio of the total accessible area to the total area of the Body Surface model as the accessibility score (AS) for the specified fiducial point in the liver. Additionally, the software calculates and visualizes the distance between the target tumor and each polygon of the accessible area on the Body Surface model.  
−  [[Media:  +  [[Media:CARS2014 Murakami.pdf]] 
<!  >  <!  >  
{{documentation/{{documentation/version}}/modulesectionUse cases}}  {{documentation/{{documentation/version}}/modulesectionUse cases}} 
Revision as of 01:16, 2 May 2014
Home < Documentation < Nightly < Extensions < PercutaneousApproachAnalysis
For the latest Slicer documentation, visit the readthedocs. 
Introduction and Acknowledgements
This work is supported in part by the National Institute of Health (R01CA111288, P01CA067165, P41RR019703, P41EB015898, R01CA124377, R01CA138586, R42CA137886).  

Module Description
The Percutaneous Approach Analysis is used to calculate and visualize the accessibility of liver tumor with a percutaneous approach. The software uses the “raytracing” method in which the target tumor serves as a light source to identify the area of the skin that allows direct approach to the target tumor with a straight needle. This software takes the Body Surface model, Obstacle model, and a fiducial point in the liver model as inputs. The software also examines each line that connects the fiducial point and the center of each polygon cell on the Body Surface model and check if the line intersects the Obstacle model. If it does not intersect, the cell is identified as an accessible area. The polygon is colored based on the accessibility to visualize the results in 3D. For quantitative analysis, the software calculates the ratio of the total accessible area to the total area of the Body Surface model as the accessibility score (AS) for the specified fiducial point in the liver. Additionally, the software calculates and visualizes the distance between the target tumor and each polygon of the accessible area on the Body Surface model.
Media:CARS2014 Murakami.pdf
Use cases
 An example using a clinical model 
1. Model preparation
Preparing required 2 models as BodySurface and Obstacle
2. Put fiducial
Putting a fiducial point at target position
3. Input and Run
Selecting an appropriate object on each parameter pulldown window and push ‘Apply’ button
If you input ‘Minimum Distance Point’ in Output field, the nearest point from the target will be displayed on the Body Surface model.
4. Output field
Accessibility score and Minimum Distance are displayed in the result field.
5. Scalar map
A color map showing approachable and inapproachable area is available.
To visualize it, a ‘visible’ checkbox should be turned on in Scalar parameter of Models module.
Tutorials
Typical use case is provided as tutorial slides.
Panels and Parameters
Parameters
 Target Point: Input an annotation fiducial point as a target of percutaneous approach.
 Obstacle Model: Input one Volume Model which you think as a barrier of needle insertion.
 Skin Model: Input one Volume Model on which the accessibile area should be measured as an inserting site.
Output/Results
 Accessibility Score: This box shows Accessibility Score which is calculated by accessibility area and total area on the selected Skin Model.
 Minimum Distance: The shortest distance between the Target Point and the surface of Skin Model.
 Minimum Distance Point: Input this when you want to know the nearest point on the Skin Model from the Target Point.
Similar Modules
N/A
References
[1] Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, Garbagnati F, Buscarini L. (1995) Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1(1): 7381
[2] Silverman SG, Tuncali K, Adams DF, van Sonnenberg E, Zou KH, Kacher DF, Morrison PR, Jolesz FA. (2000) MR Imagingguided Percutaneous Cryotherapy of Liver Tumors: Initial Experience. Radiology 217: 65764
[3] Ido K, Isoda N, Sugano K. (2001) Microwave coagulation therapy for liver cancer: laparoscopic microwave coagulation. J Gastroenterol 36(3): 14552
[4] Khlebnikov R, Kainz B, Muehl J, Schmalstieg D. (2011) Crepscular Rays for Tumor Accessibility Planning. IEEE Trans Vis Comput Graph 17(12): 216372
Information for Developers
Section under construction. 